CJC-1295 + ipamorelin

Commercial or common name

CJC-1295 + ipamorelin. This name is not standardized.

Reported formulation variants

• DAC and no-DAC versions of CJC-1295 are marketed under the same stack name

What the combination shows

No adequate human combination evidence was identified in the static MVP review. Component-level findings do not transfer to the combination.

Status

Unapproved / RUO. No approval is implied by use of a commercial or community name.

Combination trial status

No validated human combination trial identified

Stability and compatibility

Compatibility, sterility and stability are not established across marketed variants

Common marketing claims

• Growth hormone release
• Body composition
• Recovery